PPARG and chronic obstructive pulmonary disease: The study by Lea et al. in the European Respiratory Journal in 2014 underscores these findings, demonstrating that rosiglitazone, a PPARγ agonist, increases M2 macrophage polarization and enhances efferocytosis in COPD alveolar macrophages.